Clinical Trial: A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease

U.S., Nov. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07908381) titled 'A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease' on Oct. 26.

Brief Summary: Zelicapavir is a novel orally administered non-fusion replication inhibitor of RSV that is being developed for the treatment of patients with RSV infection. This phase 2b/3 study will evaluate the efficacy and safety of zelicapavir compared with placebo in adults with RSV who are at high risk for severe disease. High-risk participants include those who are either >=75 years of age or >=18 years of age with COPD and/or CHF. Participants will be non-hospitalized adult...